FibroBiologics Inc. (NASDAQ:FBLG – Free Report) – Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for FibroBiologics in a note issued to investors on Thursday, April 16th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.31) for the quarter, up from their prior estimate of ($1.40). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.49) EPS, FY2028 earnings at ($5.53) EPS, FY2029 earnings at ($6.75) EPS and FY2030 earnings at ($6.05) EPS.
A number of other analysts have also commented on the company. D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised FibroBiologics to a “sell” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $74.00.
FibroBiologics Stock Performance
Shares of FBLG stock opened at $1.53 on Monday. The business’s 50-day moving average price is $4.55 and its 200-day moving average price is $5.97. FibroBiologics has a 12 month low of $1.03 and a 12 month high of $30.60. The firm has a market capitalization of $5.37 million, a price-to-earnings ratio of -0.18 and a beta of 1.07.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.06.
Insider Activity at FibroBiologics
In related news, CFO Jason Davis acquired 3,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average cost of $8.20 per share, with a total value of $28,700.00. Following the completion of the purchase, the chief financial officer directly owned 3,500 shares in the company, valued at $28,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders purchased 9,574 shares of company stock valued at $72,886 over the last quarter. 13.00% of the stock is owned by insiders.
Hedge Funds Weigh In On FibroBiologics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of FibroBiologics in the fourth quarter worth approximately $34,000. Renaissance Technologies LLC lifted its stake in shares of FibroBiologics by 287.3% in the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after acquiring an additional 171,800 shares during the period. Geode Capital Management LLC lifted its stake in shares of FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after acquiring an additional 59,813 shares during the period. AMG National Trust Bank acquired a new position in shares of FibroBiologics in the fourth quarter worth approximately $31,000. Finally, Yorkville Advisors Global LP acquired a new position in shares of FibroBiologics in the third quarter worth approximately $278,000.
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Further Reading
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
